TOMI Environmental Solutions Regains Compliance with Nasdaq Minimum Bid Price and Stockholders’ Equity Requirements
Key Highlights
- ➤TOMI Environmental Solutions (TOMZ) regained Nasdaq minimum bid price compliance November 12, 2026
- ➤TOMI regained Nasdaq stockholders’ equity compliance under Listing Rule 5550(b)(1)
- ➤TOMZ’s Nasdaq Capital Market listing continues, subject to Hearings Panel conditions and monitoring
- ➤CEO Halden Shane cited backlog conversion, recurring SteraMist revenue, and sector expansion as priorities
Expert Statements
Halden Shane, CEO of TOMI Environmental Solutions
“We are pleased to have regained compliance with Nasdaq’s minimum bid price and stockholders’ equity requirements. Throughout 2026, we have remained focused on strengthening our capital structure, improving our operating performance and maintaining disciplined cost management. Moving forward, our focus is on converting our backlog and commercial pipeline, expanding recurring revenue across our SteraMist platform, and further advancing our expansion into the food safety, life sciences, and defense sectors as we continue to drive long-term value for our shareholders.”
FREDERICK, Md., Nov. 17, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.(®) (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced that as of November 12, 2026, the Company has regained compliance with the minimum closing bid price and stockholders’ equity requirements under Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively. Accordingly, the Company's common stock will continue to be listed on The Nasdaq Capital Market and trade under the symbol “TOMZ”. The Company’s continued listing remains subject to certain conditions and ongoing monitoring by the Nasdaq Hearings Panel.
Dr. Halden Shane, CEO of TOMI Environmental Solutions, stated, "We are pleased to have regained compliance with Nasdaq’s minimum bid price and stockholders’ equity requirements. Throughout 2026, we have remained focused on strengthening our capital structure, improving our operating performance and maintaining disciplined cost management. Moving forward, our focus is on converting our backlog and commercial pipeline, expanding recurring revenue across our SteraMist platform, and further advancing our expansion into the food safety, life sciences, and defense sectors as we continue to drive long-term value for our shareholders.”
Get started
Create a free account to read the full story.
